SCOTUS: No standing in challenge to mifepristone changes (FDA v. AHM)

confirmed Importance 6/10 ~1 min read 4 sources 2 actors

The Supreme Court unanimously held the plaintiffs lacked Article III standing to challenge FDA’s 2016/2021 actions on mifepristone, leaving the agency’s changes in place. Justice Kavanaugh delivered the opinion, with the Court finding that the Alliance for Hippocratic Medicine failed to demonstrate a concrete injury that would grant them legal standing to challenge the FDA’s regulation of the abortion medication. This ruling preserves current access to mifepristone through telemedicine and pharmacies.

Sources & Citations

[1] FDA v. Alliance for Hippocratic Medicine, 602 U.S. ___ (2024) · Jun 13, 2024 Tier 2

[2] Food and Drug Administration v. Alliance for Hippocratic Medicine · Jun 13, 2024 Tier 1

[3] Attorney General Merrick B. Garland Statement on the Supreme Court's Decision in FDA v. Alliance for Hippocratic Medicine · Jun 13, 2024 Tier 1

[4] Looking to the Future: Implications of the SCOTUS Ruling on Mifepristone · Jun 13, 2024 Tier 2

Tiers Tier 1 court records & gov docs · Tier 2 established outlets · Tier 3 regional & specialty press · Tier 4 opinion or single-source. Methodology →

Cite this entry

The Cascade Ledger. “SCOTUS: No standing in challenge to mifepristone changes (FDA v. AHM).” The Capture Cascade Timeline, June 13, 2024. https://capturecascade.org/event/2024-06-13--scotus-fda-v-ahm/